Laboratorio (Test y harrazgos) Y COVID-19

En esta página encontrarás documentos a texto completo y un enlace a la bibliografía más reciente de PubMed.

Al tener mucha información tarda unos segundos en cargarse los documentos.

Te recordamos que puedes solicitarnos cualquier artículo que necesites desde el Portal de la Biblioteca Virtual del Hospital de Getafe en https://m-hug.c17.net/ . Si no dispones de clave la puedes solicitar en https://m-hug.csinet.es/usuarios/account/sign-up/

PIIS0140673620301835.pdf

Potential Preanalytical and Analytical Vulnerabilities in the Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19)-PMID32172228.pdf

32031570 - Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan-PMID32031570.pdf

Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan China A Descriptive Study-PMID32007143.pdf

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)-PMID32198501.pdf

Laboratory abnormalities in patients with COVID-19 infection-PMID32119647.pdf

Diagnostic Testing for the Novel Coronavirus-PMID32150622.pdf

Laboratory Abnormalities in Children With Novel Coronavirus Disease 2019-32172227.pdf

32159775.pdf

Rapid Establishment of Laboratory Diagnostics for the Novel Coronavirus SARS-CoV-2 in Bavaria, Germany, February 2020.pdf

Detection of 2019 Novel Coronavirus (2019-nCoV) by Real-Time RT-PCR.pdf

Fast, portable tests come online to curb coronavirus pandemic.pdf

Developing antibody tests for SARS CoV 2_32247384.pdf.pdf

Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China, January to February 2020_32183934.pdf

Laboratory Diagnosis of Emerging Human Coronavirus Infections The State of the Art.pdf

False-Negative Results of Real-Time ReverseTranscriptase Polymerase Chain Reaction for Severe_32174053.pdf

Temperature screening to prevent COVID-19 transmission creating false security_ECRI evidence-based medicine.pdf

Strong Associations and Moderate Predictive Value of Early Symptoms for SARS-CoV-2 Test Positivity Among Healthcare Workers, the Netherlands, March 2020_32347200.pdf

Serological Assays for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), March 2020_32347204.pdf

Profile of RT-PCR for SARS-CoV-2: A Preliminary Study From 56 COVID-19 Patients_32306036.pdf

The important role of serology for COVID-19 control-32330441.pdf

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications.pdf

Hunting coronavirus SARS-CoV-2 (2019-nCoV)- from laboratory testing back to basic research_32332515.pdf

COVID-19 an Immunopathological View_32321823.pdf

Interpretación de las pruebas diagnósticas frente a SARS-Cov-2_v.2_Ministerio de Sanidad y Sociedad española de Enfermedades Infecciosas y Microbiología Clínica.pdf

Recomendaciones de SEIMC sobre uso de las pruebas de detección de anticuerpos_SEIMC.pdf

Certificados de estado serológico_SEMPSPH.pdf

#Newsletter 22 abril Susceptibilidad humana al virus SARS-CoV-2: genética, proteina AC2, NLR, inflamasomas

Attenuated SARS CoV 2 variants with deletions at the S1 S2 junction-32301390.pdf

Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2_32363011.pdf

Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients_32221523.pdf

Test 10-20 min detección anticuerpos totales contra COVID-19. Resultados 6 y 7 días. Datos sensibilidad y especificidad. EVALMED.xls

DIAGNÓSTICO MICROBIÓLOGO DE COVID-19_RECOMENDACIONES INSTITUCIONALES.pdf

SEI utilidad de medir Ac anti-SARS-cov2.pdf

Gestion rieso biologico en laboratorio que manipulen muestras con SARS-CoV-2.pdf

COVID-19: guidance for sampling and for diagnostic laboratoriesInformation for clinical diagnostic laboratories regarding safety, sampling and packaging specimens associated with COVID-19.

Clinical and Laboratory Profiles of 75 Hospitalized Patients with Novel Coronavirus Disease 2019 in Hefei, ChinaThe outbreak of the novel coronavirus disease 2019 (COVID-19) infection began in December 2019 in Wuhan, and rapidly spread to many provinces in China. The number of cases has increased markedly in Anhui, but information on the clinical characteristics of patients is limited. We reported 75 patients with COVID-19 in the First Affiliated Hospital of USTC from Jan 21 to Feb 16, 2020, Hefei, Anhui Province, China. COVID-19 infection was confirmed by real-time RT-PCR of respiratory nasopharyngeal swab samples. Epidemiological, clinical and laboratory data were collected and analyzed. Of the 75 patients with COVID-19, 61 (81.33%) had a direct or indirect exposure history to Wuhan. Common symptoms at onset included fever (66 [88.0%] of 75 patients) and dry cough (62 [82.67%]). Of the patients without fever, cough could be the only or primary symptom. The most prominent laboratory abnormalities were lymphopenia, decreased percentage of lymphocytes (LYM%), decreased CD4+ and CD8+ T cell counts, elevated C-reactive protein (CRP) and lactate dehydrogenase (LDH). Patients with elevated interleukin 6 (IL-6) showed significant decreases in the LYM%, CD4+ and CD8+ T cell counts. Besides, the percentage of neutrophils, CRP, LDH and Procalcitonin levels increased significantly. We concluded that COVID-19 could cause different degrees of hematological abnormalities and damage of internal organs. Hematological profiles including LYM, LDH, CRP and IL-6 could be indicators of diseases severity and evaluation of treatment effectiveness. Antiviral treatment requires a comprehensive and supportive approach. Further targeted therapy should be determined based on individual clinical manifestations and laboratory indicators. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work is funded by the Key Research and Development Plan Project of Anhui Science and Technology Department (YG, No. 201904b11020044). ### Author Declarations All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript. Yes All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes The data that support the findings of this study are available from the corresponding author on reasonable request.

Bibliografía más reciente aquí.

Aunque la Biblioteca del Hospital Universitario de Getafe se encuentra cerrada, seguimos dando servicio a nuestros usuarios por los diferentes canales virtuales de que disponemos. Seguimos dando acceso a los recursos de información, proporcionando artículos, realizando búsquedas bibliográficas y mucho más.

Más información y enlaces aquí:

https://ccamposhugf.wordpress.com/2020/03/18/sabes-como-comunicarte-con-la-biblioteca-del-hospital-de-getafe/

Siempre a vuestra disposición.